Philips and RealView Imaging Conclude World's First Study to Evaluate Live 3D Holographic Imaging in Interventional Cardiology

Royal Philips ElectronicsRoyal Philips (NYSE: PHG, AEX: PHIA) and RealView Imaging Ltd. have completed a clinical study that has demonstrated the feasibility of using an innovative live 3D holographic visualization and interaction technology to guide minimally-invasive structural heart disease procedures. In the pilot study that involved eight patients and was conducted in collaboration with the Schneider Children's Medical Center in Petach Tikva, Israel, RealView's innovative visualization technology was used to display interactive, real-time 3D holographic images acquired by Philips' interventional X-ray and cardiac ultrasound systems.

In addition to viewing the patient's heart on a 2D screen, doctors in the interventional team were able to view detailed dynamic 3D holographic images of the heart 'floating in free space' during a minimally-invasive structural heart disease procedure, without using special eyewear. The doctors were also able to manipulate the projected 3D heart structures by literally touching the holographic volumes in front of them. The study demonstrated the potential of the technology to enhance the context and guidance of structural heart repairs.

"The holographic projections enabled me to intuitively understand and interrogate the 3D spatial anatomy of the patient's heart, as well as to navigate and appreciate the device-tissue interaction during the procedure," said Dr. Einat Birk, pediatric cardiologist and Director of the Institute of Pediatric Cardiology at Schneider Children's Medical Center.

Dr. Elchanan Bruckheimer, pediatric cardiologist and Director of the Cardiac Catheterization Laboratories at Schneider Children's Medical Center, added: "The ability to reach into the image and apply markings on the soft tissue anatomy in the X-ray and 3D ultrasound images would be extremely useful for guidance of these complex procedures."

"Our ultimate goal is to create the future of healthcare by delivering innovative solutions that enhance clinical capabilities and improve patient outcomes," said Bert van Meurs, General Manager of Integrated Clinical Solutions and Marketing for Imaging Systems at Philips Healthcare. "By teaming up with partners that share our passion for innovation, we have been able to demonstrate the feasibility and potential value of the world's first holographic visualization technology targeted at guiding minimally invasive cardiac procedures."

"I see clear indications that 3D medical holography will play an important role in medical imaging in the near future," said Aviad Kaufman, CEO of RealView Imaging Ltd. "With the advancement of live 3D imaging and increasing clinical evidence of its value for a variety of procedures, we are convinced that our holographic technology will further enhance 3D imaging and, most importantly, improve patient care."

The technological advancements in the acquisition of live 3D images to guide minimally invasive procedures have also triggered the development of novel ways to visualize the data. Following the promising results produced by this pilot study, Philips and RealView Imaging will continue to explore the clinical value of combining live 3D imaging and medical holography, both in interventional cardiology and in other clinical areas.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs approximately 114,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About RealView Imaging
RealView Imaging Ltd. (Yokneam, Israel) is introducing the world's first 3D holographic display and interface system, initially for medical imaging applications. RealView's proprietary technology projects hyper-realistic, dynamic 3D holographic images "floating in the air" without the need for any type of eyewear or a conventional 2D screen. The projected 3D volumes appear in free space, allowing the user to literally touch and interact precisely within the image, presenting a unique and proprietary breakthrough in digital holography and real-time 3D interaction capabilities.

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...